Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
Janux Therapeutics (NASDAQ: JANX) has announced its participation in two upcoming investor conferences, offering 1x1 meetings for investors. The H.C. Wainwright BioConnect Investor Conference will be held on May 2 at NASDAQ World Headquarters in New York, while the BofA Securities 2023 Health Care Conference will take place from May 9 to May 11 in Las Vegas, featuring a corporate presentation on May 10.
Janux is developing innovative immunotherapies targeting various cancers through its proprietary TRACTr and TRACIr platforms. Lead candidates in clinical trials include JANX008, aimed at EGFR, and JANX007, targeting PSMA. Their TRACIr candidate, JANX009, is under preclinical evaluation for solid tumors. The company's goal is to create bispecific antibodies that selectively kill tumor cells while preserving healthy tissue.
- None.
- None.
Date:
Time:
Forum: 1x1 meetings
Location: NASDAQ World Headquarters,
Dates:
Forum: 1x1 meetings and corporate presentation
Presentation Time:
Location:
Janux’s TRACTr and TRACIr Pipeline
JANX008 is a TRACTr that targets EGFR and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Janux’s first clinical candidate, JANX007, is a TRACTr that targets PSMA and is being investigated in a Phase 1 clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). Janux’s TRACIr drug candidate, JANX009, is designed for targeting both the programmed death-ligand 1 (PD-L1) receptor as well as the costimulatory CD28 receptor on T cells and is being investigated in preclinical studies for the treatment of solid tumors. Janux is also applying its proprietary technology to develop a TRACTr designed to target TROP2, a clinically validated anti-tumor target that is overexpressed in various cancer types, such as breast, lung, urothelial, endometrial, ovarian, prostate, pancreatic, gastric, colon, head and neck, and glioma. In addition to named programs, Janux is generating a number of unnamed TRACTr and TRACIr programs for potential future development.
About
Janux is a clinical-stage biopharmaceutical company developing next-generation bispecific immunotherapies with the goal of fighting cancers by killing tumor cells while allowing healthy tissues to remain unharmed. Janux’s proprietary platforms develop unique Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) and support the building of a broad pipeline of drugs designed to direct and guide the patient’s immune system to eradicate tumors while minimizing safety concerns. The company's innovative technology currently focuses on the engineering of bispecific antibodies functional only in the tumor, providing safety advantages compared to earlier generations of bispecific immunotherapies. Currently, Janux’s two lead TRACTr compounds for PSMA and EGFR are in the clinic. For more information, please visit www.januxrx.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230424005872/en/
Investors:
ameyer@januxrx.com
(202) 215-2579
Media:
jessica@litldog.com
(858) 344-8091
Source:
FAQ
What are the upcoming investor conferences for Janux Therapeutics?
When is Janux's corporate presentation during the BofA Securities conference?
What are Janux Therapeutics' lead clinical candidates?
What is the focus of Janux's TRACIr candidate JANX009?
What innovative technologies does Janux Therapeutics utilize?
